BioLineRx Ltd. (BLRX) 10-Year Financial Performance & Capital Metrics

BLRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Show more

Revenue $29M +502.9%
EBITDA -$16M +66.2%
Net Income -$9M +84.8%
EPS (Diluted) -0.12 +87.2%
Gross Margin 67.99% +194.6%
EBITDA Margin -56.47% +94.4%
Operating Margin -70.52% +93.2%
Net Margin -31.86% +97.5%
ROE -69.11% +63.5%
ROIC -79.26% +22.2%
Debt/Equity 1.12 +27.5%
Interest Coverage -2.23 +90.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 16 (bottom 16%)
✗Shares diluted 24.4% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 17.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM1.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM74.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM-131.68%

ROCE

10Y Avg-59.95%

5Y Avg-70.53%

3Y Avg-82.77%

Latest-91.43%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	4.8M	28.94M
Revenue Growth %	-	-	-	-	-	-	-	-	-	5.03%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	3.69M	9.26M
COGS % of Revenue	-	-	-	-	-	-	-	-	0.77%	0.32%
Gross Profit+	0	0	0	0	0	0	0	0	1.11M	19.68M
Gross Margin %	-	-	-	-	-	-	-	-	0.23%	0.68%
Gross Profit Growth %	1%	-	-	-	-	-	-	-	-	16.76%
Operating Expenses+	16.2M	16.51M	25.24M	25.61M	28.11M	22.93M	24.78M	29.16M	50.8M	40.09M
OpEx % of Revenue	-	-	-	-	-	-	-	-	10.58%	1.39%
Selling, General & Admin	4.65M	5.31M	5.73M	5.77M	4.59M	4.68M	5.27M	11.53M	31.23M	28.54M
SG&A % of Revenue	-	-	-	-	-	-	-	-	6.51%	0.99%
Research & Development	11.49M	11.18M	19.51M	19.81M	23.44M	18.17M	19.47M	17.63M	12.52M	9.15M
R&D % of Revenue	-	-	-	-	-	-	-	-	2.61%	0.32%
Other Operating Expenses	57K	30K	0	27K	78K	70K	42K	0	7.05M	2.4M
Operating Income+	-16.2M	-16.51M	-25.24M	-25.61M	-28.11M	-22.93M	-24.78M	-29.16M	-49.69M	-20.41M
Operating Margin %	-	-	-	-	-	-	-	-	-10.35%	-0.71%
Operating Income Growth %	0.06%	-0.02%	-0.53%	-0.01%	-0.1%	0.18%	-0.08%	-0.18%	-0.7%	0.59%
EBITDA+	-15.76M	-16.03M	-24.8M	-25.15M	-27.17M	-21.99M	-24.07M	-28.5M	-48.31M	-16.34M
EBITDA Margin %	-	-	-	-	-	-	-	-	-10.06%	-0.56%
EBITDA Growth %	0.07%	-0.02%	-0.55%	-0.01%	-0.08%	0.19%	-0.09%	-0.18%	-0.69%	0.66%
D&A (Non-Cash Add-back)	441K	481.89K	438K	451K	940K	934K	703K	654K	1.38M	4.07M
EBIT	-16.2M	-16.51M	-25.24M	-22.49M	-23.59M	-28.53M	-24.78M	-29.16M	-58.47M	-147K
Net Interest Income+	442K	466K	1.15M	698K	-1.05M	-1.23M	-425K	-1.46M	-162K	-7.33M
Interest Income	457K	480K	1.17M	719K	777K	236K	559K	694K	2.01M	1.83M
Interest Expense	15K	14K	21K	21K	1.83M	1.47M	984K	2.16M	2.17M	9.16M
Other Income/Expense	1.8M	672K	888K	2.64M	2.67M	-7.09M	-2.28M	4.21M	-10.92M	11.19M
Pretax Income+	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Pretax Margin %	-	-	-	-	-	-	-	-	-12.63%	-0.32%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Net Margin %	-	-	-	-	-	-	-	-	-12.63%	-0.32%
Net Income Growth %	-0.42%	-0.1%	-0.54%	0.06%	-0.11%	-0.18%	0.1%	0.08%	-1.43%	0.85%
Net Income (Continuing)	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.20	-4.20	-4.05	-3.15	-2.70	-1.80	-0.61	-0.48	-0.94	-0.12
EPS Growth %	0.1%	0%	0.04%	0.22%	0.14%	0.33%	0.66%	0.21%	-0.96%	0.87%
EPS (Basic)	-4.20	-4.20	-4.05	-3.15	-2.70	-1.80	-0.61	-0.48	-0.94	-0.12
Diluted Shares Outstanding	3.43M	3.74M	6M	7.24M	9.76M	16.86M	44.2M	51.6M	64.22M	79.87M
Basic Shares Outstanding	3.43M	3.74M	6M	7.24M	9.76M	16.86M	44.2M	51.6M	64.22M	79.87M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.18M	36.1M	50.38M	31.98M	28.21M	22.88M	57.4M	52M	47.18M	27.1M
Cash & Short-Term Investments	47.66M	35.62M	49.48M	30.15M	27.49M	22.59M	57.13M	51.08M	42.99M	19.56M
Cash Only	5.54M	2.47M	5.11M	3.4M	5.3M	16.83M	12.99M	10.59M	4.25M	10.44M
Short-Term Investments	42.12M	33.15M	44.37M	26.75M	22.19M	5.76M	44.15M	40.49M	38.74M	9.13M
Accounts Receivable	291K	223K	586K	1.34M	613K	141K	142K	721K	708K	3.86M
Days Sales Outstanding	-	-	-	-	-	-	-	-	53.84	48.72
Inventory	0	0	0	0	107.28K	0	126.73K	197.08K	1.95M	3.15M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	193.08	123.93
Other Current Assets	0	0	0	0	-107.28K	0	-126.73K	-197.08K	480K	0
Total Non-Current Assets+	3.12M	2.84M	10.59M	24.25M	25.36M	24.41M	23.99M	24.38M	16.74M	11.8M
Property, Plant & Equipment	2.91M	2.6M	2.5M	2.23M	3.47M	2.7M	2.28M	2.5M	1.89M	1.35M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	2.54x	21.39x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	152K	181K	7.02M	21.97M	21.89M	21.71M	21.7M	21.89M	14.85M	10.45M
Long-Term Investments	0	0	1M	0	0	0	0	0	0	0
Other Non-Current Assets	58K	52K	61K	56K	0	0	0	0	0	0
Total Assets+	51.3M	38.94M	60.97M	56.23M	53.57M	47.29M	81.39M	76.38M	63.92M	38.91M
Asset Turnover	-	-	-	-	-	-	-	-	0.08x	0.74x
Asset Growth %	0.42%	-0.24%	0.57%	-0.08%	-0.05%	-0.12%	0.72%	-0.06%	-0.16%	-0.39%
Total Current Liabilities+	3.14M	3.66M	6.72M	6.75M	11.97M	10.64M	9.72M	10.68M	42.78M	15.41M
Accounts Payable	1.91M	2.59M	5.52M	4.49M	7.79M	5.92M	5.57M	6.97M	10.87M	5.58M
Days Payables Outstanding	-	-	-	-	-	-	-	-	1.07K	219.99
Short-Term Debt	93K	93K	93K	895K	2.69M	3.09M	2.76M	1.54M	3.15M	4.48M
Deferred Revenue (Current)	0	0	0	0	1000K	0	0	0	1000K	0
Other Current Liabilities	10K	15K	19K	14K	-1.27M	3K	2K	84K	12.35M	2.12M
Current Ratio	15.34x	9.86x	7.49x	4.74x	2.36x	2.15x	5.91x	4.87x	1.10x	1.76x
Quick Ratio	15.34x	9.86x	7.49x	4.74x	2.35x	2.15x	5.89x	4.85x	1.06x	1.56x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-827.62	-47.35
Total Non-Current Liabilities+	552K	251K	1.36M	8.16M	8.22M	14.62M	3.58M	14.86M	19.85M	10.04M
Long-Term Debt	344K	250K	157K	7.84M	5.8M	2.74M	0	8.63M	6.63M	8.96M
Capital Lease Obligations	0	0	0	0	1.76M	1.66M	1.73M	1.73M	1.29M	1.08M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	208K	1K	1.21M	323K	658K	10.22M	1.86M	4.51M	11.93M	0
Total Liabilities	3.69M	3.91M	8.08M	14.91M	20.19M	25.26M	13.3M	25.54M	50.7M	25.45M
Total Debt+	437K	343K	250K	8.73M	10.46M	7.68M	4.65M	12.32M	11.59M	15.04M
Net Debt	-5.11M	-2.13M	-4.86M	5.33M	5.16M	-9.15M	-8.34M	1.74M	7.34M	4.6M
Debt / Equity	0.01x	0.01x	0.00x	0.21x	0.31x	0.35x	0.07x	0.24x	0.88x	1.12x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1079.73x	-1179.50x	-1201.90x	-1219.29x	-15.37x	-15.60x	-25.18x	-13.51x	-22.91x	-2.23x
Total Equity+	47.61M	35.03M	52.88M	41.32M	33.38M	22.03M	68.09M	50.84M	13.22M	13.46M
Equity Growth %	0.5%	-0.26%	0.51%	-0.22%	-0.19%	-0.34%	2.09%	-0.25%	-0.74%	0.02%
Book Value per Share	13.89	9.36	8.82	5.71	3.42	1.31	1.54	0.99	0.21	0.17
Total Shareholders' Equity	47.61M	35.03M	52.88M	41.32M	33.38M	22.03M	68.09M	50.84M	13.22M	13.46M
Common Stock	1.46M	1.51M	2.84M	3.11M	4.69M	9.87M	21.07M	27.1M	31.36M	38.1M
Retained Earnings	-159.37M	-175.21M	-199.56M	-222.52M	-247.97M	-277.99M	-305.04M	-329.99M	-390.61M	-399.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	9.32M	9.15M	8.92M	10.54M	10.72M	10.91M	12.72M	14.76M	16.99M	16.13M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.17M	-14.51M	-20.55M	-24.19M	-22.67M	-23.21M	-23.57M	-26.24M	-22.61M	-43.87M
Operating CF Margin %	-	-	-	-	-	-	-	-	-4.71%	-1.52%
Operating CF Growth %	0.02%	-0.02%	-0.42%	-0.18%	0.06%	-0.02%	-0.02%	-0.11%	0.14%	-0.94%
Net Income	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Depreciation & Amortization	441K	482K	481K	545K	940K	934K	703K	654K	1.38M	4.07M
Stock-Based Compensation	1.15M	1.07M	1.51M	2.53M	1.76M	1.27M	1.5M	2.25M	2.32M	1.14M
Deferred Taxes	-1.32M	-258K	-291K	-2.08M	-4.17M	5.66M	1.78M	0	0	0
Other Non-Cash Items	-190K	-382K	-539K	-517K	-72K	242K	39K	-5.43M	19.1M	-18.03M
Working Capital Changes	154K	411K	2.65M	-1.71M	4.32M	-1.29M	-540K	1.24M	15.2M	-21.82M
Change in Receivables	-42K	0	0	-934K	0	0	0	0	-358K	-2.12M
Change in Inventory	0	0	0	0	0	0	0	0	-1.95M	-1.19M
Change in Payables	0	0	0	-773K	0	0	0	0	4.55M	0
Cash from Investing+	-15.6M	9.3M	-15.93M	9.55M	5.26M	16.67M	-38.22M	4.01M	1.44M	29.37M
Capital Expenditures	-2.72M	-55K	-4.24M	-10.22M	-73K	0	-97K	-316K	-116K	-53K
CapEx % of Revenue	-	-	-	-	-	-	-	-	0.02%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	202K	-3K	0	-1.5M	-6K	0	-38.13K	4.14K	-181K	-1K
Cash from Financing+	29.49M	2.09M	38.68M	13.1M	19.19M	17.87M	57.75M	20.44M	15.06M	20.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	46K	1K	1.98M	10.91M	5K	2.96M	22K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.89M	-14.57M	-24.79M	-34.41M	-22.74M	-23.21M	-23.67M	-26.56M	-22.91M	-43.93M
FCF Margin %	-	-	-	-	-	-	-	-	-4.77%	-1.52%
FCF Growth %	-0.15%	0.14%	-0.7%	-0.39%	0.34%	-0.02%	-0.02%	-0.12%	0.14%	-0.92%
FCF per Share	-4.93	-3.89	-4.13	-4.75	-2.33	-1.38	-0.54	-0.51	-0.36	-0.55
FCF Conversion (FCF/Net Income)	0.98x	0.92x	0.84x	1.05x	0.89x	0.77x	0.87x	1.05x	0.37x	4.76x
Interest Paid	0	0	0	0	0	0	0	0	0	10.39M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.28%	-38.34%	-55.4%	-48.75%	-68.13%	-108.36%	-60.04%	-41.96%	-189.23%	-69.11%
Return on Invested Capital (ROIC)	-35.47%	-32.85%	-46.79%	-40.57%	-49.5%	-66.88%	-51.17%	-38.94%	-101.92%	-79.26%
Gross Margin	-	-	-	-	-	-	-	-	23.08%	67.99%
Net Margin	-	-	-	-	-	-	-	-	-1262.79%	-31.86%
Debt / Equity	0.01x	0.01x	0.00x	0.21x	0.31x	0.35x	0.07x	0.24x	0.88x	1.12x
Interest Coverage	-1079.73x	-1179.50x	-1201.90x	-1219.29x	-15.37x	-15.60x	-25.18x	-13.51x	-22.91x	-2.23x
FCF Conversion	0.98x	0.92x	0.84x	1.05x	0.89x	0.77x	0.87x	1.05x	0.37x	4.76x
Revenue Growth	-	-	-	-	-	-	-	-	-	502.92%

Frequently Asked Questions

Growth & Financials

BioLineRx Ltd. (BLRX) reported $17.3M in revenue for fiscal year 2024.

BioLineRx Ltd. (BLRX) grew revenue by 502.9% over the past year. This is strong growth.

BioLineRx Ltd. (BLRX) reported a net loss of $7.8M for fiscal year 2024.

Dividend & Returns

BioLineRx Ltd. (BLRX) has a return on equity (ROE) of -69.1%. Negative ROE indicates the company is unprofitable.

BioLineRx Ltd. (BLRX) had negative free cash flow of $21.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BioLineRx Ltd. (BLRX) 10-Year Financial Performance & Capital Metrics

BLRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $29M +502.9%
EBITDA -$16M +66.2%
Net Income -$9M +84.8%
EPS (Diluted) -0.12 +87.2%
Gross Margin 67.99% +194.6%
EBITDA Margin -56.47% +94.4%
Operating Margin -70.52% +93.2%
Net Margin -31.86% +97.5%
ROE -69.11% +63.5%
ROIC -79.26% +22.2%
Debt/Equity 1.12 +27.5%
Interest Coverage -2.23 +90.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 16 (bottom 16%)
✗Shares diluted 24.4% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 17.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM1.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM74.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM-131.68%

ROCE

10Y Avg-59.95%

5Y Avg-70.53%

3Y Avg-82.77%

Latest-91.43%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	4.8M	28.94M
Revenue Growth %	-	-	-	-	-	-	-	-	-	5.03%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	3.69M	9.26M
COGS % of Revenue	-	-	-	-	-	-	-	-	0.77%	0.32%
Gross Profit+	0	0	0	0	0	0	0	0	1.11M	19.68M
Gross Margin %	-	-	-	-	-	-	-	-	0.23%	0.68%
Gross Profit Growth %	1%	-	-	-	-	-	-	-	-	16.76%
Operating Expenses+	16.2M	16.51M	25.24M	25.61M	28.11M	22.93M	24.78M	29.16M	50.8M	40.09M
OpEx % of Revenue	-	-	-	-	-	-	-	-	10.58%	1.39%
Selling, General & Admin	4.65M	5.31M	5.73M	5.77M	4.59M	4.68M	5.27M	11.53M	31.23M	28.54M
SG&A % of Revenue	-	-	-	-	-	-	-	-	6.51%	0.99%
Research & Development	11.49M	11.18M	19.51M	19.81M	23.44M	18.17M	19.47M	17.63M	12.52M	9.15M
R&D % of Revenue	-	-	-	-	-	-	-	-	2.61%	0.32%
Other Operating Expenses	57K	30K	0	27K	78K	70K	42K	0	7.05M	2.4M
Operating Income+	-16.2M	-16.51M	-25.24M	-25.61M	-28.11M	-22.93M	-24.78M	-29.16M	-49.69M	-20.41M
Operating Margin %	-	-	-	-	-	-	-	-	-10.35%	-0.71%
Operating Income Growth %	0.06%	-0.02%	-0.53%	-0.01%	-0.1%	0.18%	-0.08%	-0.18%	-0.7%	0.59%
EBITDA+	-15.76M	-16.03M	-24.8M	-25.15M	-27.17M	-21.99M	-24.07M	-28.5M	-48.31M	-16.34M
EBITDA Margin %	-	-	-	-	-	-	-	-	-10.06%	-0.56%
EBITDA Growth %	0.07%	-0.02%	-0.55%	-0.01%	-0.08%	0.19%	-0.09%	-0.18%	-0.69%	0.66%
D&A (Non-Cash Add-back)	441K	481.89K	438K	451K	940K	934K	703K	654K	1.38M	4.07M
EBIT	-16.2M	-16.51M	-25.24M	-22.49M	-23.59M	-28.53M	-24.78M	-29.16M	-58.47M	-147K
Net Interest Income+	442K	466K	1.15M	698K	-1.05M	-1.23M	-425K	-1.46M	-162K	-7.33M
Interest Income	457K	480K	1.17M	719K	777K	236K	559K	694K	2.01M	1.83M
Interest Expense	15K	14K	21K	21K	1.83M	1.47M	984K	2.16M	2.17M	9.16M
Other Income/Expense	1.8M	672K	888K	2.64M	2.67M	-7.09M	-2.28M	4.21M	-10.92M	11.19M
Pretax Income+	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Pretax Margin %	-	-	-	-	-	-	-	-	-12.63%	-0.32%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Net Margin %	-	-	-	-	-	-	-	-	-12.63%	-0.32%
Net Income Growth %	-0.42%	-0.1%	-0.54%	0.06%	-0.11%	-0.18%	0.1%	0.08%	-1.43%	0.85%
Net Income (Continuing)	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.20	-4.20	-4.05	-3.15	-2.70	-1.80	-0.61	-0.48	-0.94	-0.12
EPS Growth %	0.1%	0%	0.04%	0.22%	0.14%	0.33%	0.66%	0.21%	-0.96%	0.87%
EPS (Basic)	-4.20	-4.20	-4.05	-3.15	-2.70	-1.80	-0.61	-0.48	-0.94	-0.12
Diluted Shares Outstanding	3.43M	3.74M	6M	7.24M	9.76M	16.86M	44.2M	51.6M	64.22M	79.87M
Basic Shares Outstanding	3.43M	3.74M	6M	7.24M	9.76M	16.86M	44.2M	51.6M	64.22M	79.87M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	48.18M	36.1M	50.38M	31.98M	28.21M	22.88M	57.4M	52M	47.18M	27.1M
Cash & Short-Term Investments	47.66M	35.62M	49.48M	30.15M	27.49M	22.59M	57.13M	51.08M	42.99M	19.56M
Cash Only	5.54M	2.47M	5.11M	3.4M	5.3M	16.83M	12.99M	10.59M	4.25M	10.44M
Short-Term Investments	42.12M	33.15M	44.37M	26.75M	22.19M	5.76M	44.15M	40.49M	38.74M	9.13M
Accounts Receivable	291K	223K	586K	1.34M	613K	141K	142K	721K	708K	3.86M
Days Sales Outstanding	-	-	-	-	-	-	-	-	53.84	48.72
Inventory	0	0	0	0	107.28K	0	126.73K	197.08K	1.95M	3.15M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	193.08	123.93
Other Current Assets	0	0	0	0	-107.28K	0	-126.73K	-197.08K	480K	0
Total Non-Current Assets+	3.12M	2.84M	10.59M	24.25M	25.36M	24.41M	23.99M	24.38M	16.74M	11.8M
Property, Plant & Equipment	2.91M	2.6M	2.5M	2.23M	3.47M	2.7M	2.28M	2.5M	1.89M	1.35M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	2.54x	21.39x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	152K	181K	7.02M	21.97M	21.89M	21.71M	21.7M	21.89M	14.85M	10.45M
Long-Term Investments	0	0	1M	0	0	0	0	0	0	0
Other Non-Current Assets	58K	52K	61K	56K	0	0	0	0	0	0
Total Assets+	51.3M	38.94M	60.97M	56.23M	53.57M	47.29M	81.39M	76.38M	63.92M	38.91M
Asset Turnover	-	-	-	-	-	-	-	-	0.08x	0.74x
Asset Growth %	0.42%	-0.24%	0.57%	-0.08%	-0.05%	-0.12%	0.72%	-0.06%	-0.16%	-0.39%
Total Current Liabilities+	3.14M	3.66M	6.72M	6.75M	11.97M	10.64M	9.72M	10.68M	42.78M	15.41M
Accounts Payable	1.91M	2.59M	5.52M	4.49M	7.79M	5.92M	5.57M	6.97M	10.87M	5.58M
Days Payables Outstanding	-	-	-	-	-	-	-	-	1.07K	219.99
Short-Term Debt	93K	93K	93K	895K	2.69M	3.09M	2.76M	1.54M	3.15M	4.48M
Deferred Revenue (Current)	0	0	0	0	1000K	0	0	0	1000K	0
Other Current Liabilities	10K	15K	19K	14K	-1.27M	3K	2K	84K	12.35M	2.12M
Current Ratio	15.34x	9.86x	7.49x	4.74x	2.36x	2.15x	5.91x	4.87x	1.10x	1.76x
Quick Ratio	15.34x	9.86x	7.49x	4.74x	2.35x	2.15x	5.89x	4.85x	1.06x	1.56x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-827.62	-47.35
Total Non-Current Liabilities+	552K	251K	1.36M	8.16M	8.22M	14.62M	3.58M	14.86M	19.85M	10.04M
Long-Term Debt	344K	250K	157K	7.84M	5.8M	2.74M	0	8.63M	6.63M	8.96M
Capital Lease Obligations	0	0	0	0	1.76M	1.66M	1.73M	1.73M	1.29M	1.08M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	208K	1K	1.21M	323K	658K	10.22M	1.86M	4.51M	11.93M	0
Total Liabilities	3.69M	3.91M	8.08M	14.91M	20.19M	25.26M	13.3M	25.54M	50.7M	25.45M
Total Debt+	437K	343K	250K	8.73M	10.46M	7.68M	4.65M	12.32M	11.59M	15.04M
Net Debt	-5.11M	-2.13M	-4.86M	5.33M	5.16M	-9.15M	-8.34M	1.74M	7.34M	4.6M
Debt / Equity	0.01x	0.01x	0.00x	0.21x	0.31x	0.35x	0.07x	0.24x	0.88x	1.12x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1079.73x	-1179.50x	-1201.90x	-1219.29x	-15.37x	-15.60x	-25.18x	-13.51x	-22.91x	-2.23x
Total Equity+	47.61M	35.03M	52.88M	41.32M	33.38M	22.03M	68.09M	50.84M	13.22M	13.46M
Equity Growth %	0.5%	-0.26%	0.51%	-0.22%	-0.19%	-0.34%	2.09%	-0.25%	-0.74%	0.02%
Book Value per Share	13.89	9.36	8.82	5.71	3.42	1.31	1.54	0.99	0.21	0.17
Total Shareholders' Equity	47.61M	35.03M	52.88M	41.32M	33.38M	22.03M	68.09M	50.84M	13.22M	13.46M
Common Stock	1.46M	1.51M	2.84M	3.11M	4.69M	9.87M	21.07M	27.1M	31.36M	38.1M
Retained Earnings	-159.37M	-175.21M	-199.56M	-222.52M	-247.97M	-277.99M	-305.04M	-329.99M	-390.61M	-399.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	9.32M	9.15M	8.92M	10.54M	10.72M	10.91M	12.72M	14.76M	16.99M	16.13M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.17M	-14.51M	-20.55M	-24.19M	-22.67M	-23.21M	-23.57M	-26.24M	-22.61M	-43.87M
Operating CF Margin %	-	-	-	-	-	-	-	-	-4.71%	-1.52%
Operating CF Growth %	0.02%	-0.02%	-0.42%	-0.18%	0.06%	-0.02%	-0.02%	-0.11%	0.14%	-0.94%
Net Income	-14.4M	-15.84M	-24.35M	-22.96M	-25.45M	-30.02M	-27.05M	-24.95M	-60.61M	-9.22M
Depreciation & Amortization	441K	482K	481K	545K	940K	934K	703K	654K	1.38M	4.07M
Stock-Based Compensation	1.15M	1.07M	1.51M	2.53M	1.76M	1.27M	1.5M	2.25M	2.32M	1.14M
Deferred Taxes	-1.32M	-258K	-291K	-2.08M	-4.17M	5.66M	1.78M	0	0	0
Other Non-Cash Items	-190K	-382K	-539K	-517K	-72K	242K	39K	-5.43M	19.1M	-18.03M
Working Capital Changes	154K	411K	2.65M	-1.71M	4.32M	-1.29M	-540K	1.24M	15.2M	-21.82M
Change in Receivables	-42K	0	0	-934K	0	0	0	0	-358K	-2.12M
Change in Inventory	0	0	0	0	0	0	0	0	-1.95M	-1.19M
Change in Payables	0	0	0	-773K	0	0	0	0	4.55M	0
Cash from Investing+	-15.6M	9.3M	-15.93M	9.55M	5.26M	16.67M	-38.22M	4.01M	1.44M	29.37M
Capital Expenditures	-2.72M	-55K	-4.24M	-10.22M	-73K	0	-97K	-316K	-116K	-53K
CapEx % of Revenue	-	-	-	-	-	-	-	-	0.02%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	202K	-3K	0	-1.5M	-6K	0	-38.13K	4.14K	-181K	-1K
Cash from Financing+	29.49M	2.09M	38.68M	13.1M	19.19M	17.87M	57.75M	20.44M	15.06M	20.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	46K	1K	1.98M	10.91M	5K	2.96M	22K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.89M	-14.57M	-24.79M	-34.41M	-22.74M	-23.21M	-23.67M	-26.56M	-22.91M	-43.93M
FCF Margin %	-	-	-	-	-	-	-	-	-4.77%	-1.52%
FCF Growth %	-0.15%	0.14%	-0.7%	-0.39%	0.34%	-0.02%	-0.02%	-0.12%	0.14%	-0.92%
FCF per Share	-4.93	-3.89	-4.13	-4.75	-2.33	-1.38	-0.54	-0.51	-0.36	-0.55
FCF Conversion (FCF/Net Income)	0.98x	0.92x	0.84x	1.05x	0.89x	0.77x	0.87x	1.05x	0.37x	4.76x
Interest Paid	0	0	0	0	0	0	0	0	0	10.39M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.28%	-38.34%	-55.4%	-48.75%	-68.13%	-108.36%	-60.04%	-41.96%	-189.23%	-69.11%
Return on Invested Capital (ROIC)	-35.47%	-32.85%	-46.79%	-40.57%	-49.5%	-66.88%	-51.17%	-38.94%	-101.92%	-79.26%
Gross Margin	-	-	-	-	-	-	-	-	23.08%	67.99%
Net Margin	-	-	-	-	-	-	-	-	-1262.79%	-31.86%
Debt / Equity	0.01x	0.01x	0.00x	0.21x	0.31x	0.35x	0.07x	0.24x	0.88x	1.12x
Interest Coverage	-1079.73x	-1179.50x	-1201.90x	-1219.29x	-15.37x	-15.60x	-25.18x	-13.51x	-22.91x	-2.23x
FCF Conversion	0.98x	0.92x	0.84x	1.05x	0.89x	0.77x	0.87x	1.05x	0.37x	4.76x
Revenue Growth	-	-	-	-	-	-	-	-	-	502.92%

Frequently Asked Questions

Growth & Financials

BioLineRx Ltd. (BLRX) reported $17.3M in revenue for fiscal year 2024.

BioLineRx Ltd. (BLRX) grew revenue by 502.9% over the past year. This is strong growth.

BioLineRx Ltd. (BLRX) reported a net loss of $7.8M for fiscal year 2024.

Dividend & Returns

BioLineRx Ltd. (BLRX) has a return on equity (ROE) of -69.1%. Negative ROE indicates the company is unprofitable.

BioLineRx Ltd. (BLRX) had negative free cash flow of $21.2M in fiscal year 2024, likely due to heavy capital investments.